ATL 1101

Drug Profile

ATL 1101

Alternative Names: ATL1101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Murdoch Childrens Research Institute
  • Developer Antisense Therapeutics; University of British Columbia; Vancouver General Hospital
  • Class Antineoplastics; Antipsoriatics; Antisense oligonucleotides
  • Mechanism of Action Insulin-like growth factor I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer
  • Discontinued Psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in Canada (SC, Injection)
  • 02 Jun 2014 Preclinical development is ongoing for Prostate cancer
  • 20 Jul 2012 The option period has expired for Afandin's option to license agreement with Antisense Therapeutics for ATL 1101, with no extension of the agreement available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top